An Expert's Thoughts on the FDA Approval of Durvalumab in Locally Advanced Lung Cancers
April 9th 2018Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the recent FDA approval of durvalumab (Imfinzi) for the treatment of patients with locally advanced, unresectable stage III non–small cell lung cancer.
Watch
Recognizing Immunotherapy Side Effects in the Community Setting
April 9th 2018David M. Nanus, MD, chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine, discusses the use of immunotherapy in the community setting. He also gives advice to community oncologists that are using these treatments in their practice. <br />
Watch
Gamble Discusses Exciting Topics at the Upcoming 2018 Community Oncology Conference
April 6th 2018Robert "Bo" Gamble, director of Strategic Practice Initiatives, Community Oncology Alliance (COA), discusses some of the exciting topics that will be covered during the upcoming 2018 Community Oncology Conference.
Watch
Experts Share Their Key Takeaways from the 2018 SGO Annual Meeting
April 4th 2018Experts in the gynecologic oncology field share their key takeaways from the 2018 Society of Gynecologic Oncology (SGO) Annual Meeting on Women’s Cancer, held at the Hyatt Regency Resort & Convention Center in New Orleans, Louisiana, from March 24 to 27, 2018.
Watch
Future Possibilities for CAR T Cells in Non-Hodgkin's Lymphoma
April 4th 2018Miguel-Angel Perales, MD, deputy chief of Adult Bone Marrow Transplant Service at Memorial Sloan Kettering Cancer Center, discusses what experts are expecting to change in the treatment landscape of non-Hodgkin’s lymphoma in the next year. Perales says by the end of 2018, there may be 3 CAR T-cell therapies approved for the treatment of non-Hodgkin’s lymphoma.
Watch
Findings Confirm Opioids Decrease After Restrictive Protocol Takes Effect
April 3rd 2018Jaron Mark, MD, gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses findings from a restrictive protocol that limited the number of opioids prescribed after gynecologic surgeries. Patients looked at in this trial had undergone ambulatory or minimally invasive procedures.
Watch